World Journal of Urology

, Volume 33, Issue 7, pp 965–971 | Cite as

Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer

  • Souhil LebdaiEmail author
  • Arnaud Villers
  • Eric Barret
  • Cosmina Nedelcu
  • Pierre Bigot
  • Abdel-Rahmène Azzouzi
Topic Paper



To investigate feasibility, safety, and efficacy of salvage radical prostatectomy (RP) for recurrent prostate cancer (PCa) after focal treatment with TOOKAD® Soluble vascular-targeted photodynamic therapy (VTP).


Nineteen patients underwent RP after biopsy-proven PCa post-focal VTP. We reported: operation time, blood loss, transfusion, complications, urethral catheterization time, functional outcomes, and short-term oncologic outcomes.


Median age was 64 years (58–70). Median PSA before VTP was 6.30 ng/ml (3.20–9.80). Median delay between VTP and RP was 17 months (8–48). Median blood loss was 400 ml (100–1,000). Median operation time was 150 min (90–210), median urethral catheterization time was 7 days (5–18), and median hospital stay was 7 days (4–21). There was no perioperative mortality. Three patients had related per-operative complications: one pelvic hematoma (150 cc) (Clavien IIIa), one per-operative transfusion (900 cc hemorrhage) (Clavien II), and one superficial wound infection (Clavien I). After a median follow-up of 10 months (1–46), 13 were completely continent (68 %), five needed ≤1 pad/day, and one needed 3 pads/day (Clavien I). Severe erectile dysfunction was observed before and after RP (respectively 8 and 18). Ten patients regained potency with appropriate treatment. Median postoperative PSA was 0.02 ng/ml (<0.01–0.38) and remained undetectable for 16 patients (84 %). Nine patients had positive margins and six underwent complementary radiotherapy. Positive margins were significantly associated with bilateral VTP [risk ratio = 4.3, 95 % confidence interval (1.6–11.7), p = 0.003].


Salvage RP after VTP treatment was feasible, safe, and efficient to treat most of the locally recurrent PCa. Short-term oncologic and functional outcomes were promising, but further studies are required.


Salvage therapy Radical prostatectomy Prostate cancer Focal therapy WST11 TOOKAD® Soluble Vascular-targeted photodynamic therapy 



We thank Pr Guy, Pr Bouchot, Dr. Barré, Dr. Navara, and Dr. Mandron for their collaboration.

Conflict of interest

Pr Azzouzi is investigator and proctor for Steba Biotech. Pr Villers is lecturer for Steba Biotech. All other authors have no conflict of interest related to this study.

Ethical standard

Ethical and regulatory approvals were sought and obtained from the relevant national and local authorities.


  1. 1.
    Ferlay JS-FE, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2012) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013:1374–1403Google Scholar
  2. 2.
    Jemal A, Siegel R, Ward E et al (2008) Cancer statistics. CA Cancer J Clin 58:71–96PubMedCrossRefGoogle Scholar
  3. 3.
    Sanda MG, Dunn RL, Michalski J et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 20(358):1250–1261CrossRefGoogle Scholar
  4. 4.
    Choo R, Klotz L, Danjoux C et al (2002) Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167:1664–1669PubMedCrossRefGoogle Scholar
  5. 5.
    Moore CM, Pendse D, Emberton M (2009) Photodynamic therapy for prostate cancer–a review of current status and future promise. Nat Clin Pract Urol 6:18–30PubMedCrossRefGoogle Scholar
  6. 6.
    Azzouzi AR, Barret E, Moore CM et al (2013) TOOKAD((R)) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int 112:766–774PubMedCrossRefGoogle Scholar
  7. 7.
    Eymerit-Morin C, Zidane M, Lebdai S, Triau S, Azzouzi AR, Rousselet MC (2013) Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer. Virchows Arch 463(4):547–552Google Scholar
  8. 8.
    Moore CM, Azzouzi AR, Barret E et al (2014) Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localized prostate cancer using WST11-Vascular Targeted Photodynamic (VTP) therapy. BJU Int. doi: 10.1111/bju.12816
  9. 9.
    Heidenreich A, Bellmunt J, Bolla M, Joniau S et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 65(1):124–137Google Scholar
  10. 10.
    Thomas C, Jones J, Jager W, Hampel C, Thuroff JW, Gillitzer R (2010) Incidence, clinical symptoms and management of rectourethral fistulas after radical prostatectomy. J Urol 183:608–612PubMedCrossRefGoogle Scholar
  11. 11.
    Salomon L, Azria D, Bastide C et al (2010) Recommendations Onco-Urology 2010: prostate cancer. Prog Urol 20(Suppl 4):S217–S251PubMedCrossRefGoogle Scholar
  12. 12.
    Ficarra V, Novara G, Artibani W et al (2009) Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 55:1037–1063PubMedCrossRefGoogle Scholar
  13. 13.
    Leonardo C, Franco G, De Nunzio C et al (2012) Salvage laparoscopic radical prostatectomy following high-intensity focused ultrasound for treatment of prostate cancer. Urology 80:130–133PubMedCrossRefGoogle Scholar
  14. 14.
    Gotto GT, Yunis LH, Vora K, Eastham JA, Scardino PT, Rabbani F (2010) Impact of prior prostate radiation on complications after radical prostatectomy. J Urol 184:136–142PubMedCrossRefGoogle Scholar
  15. 15.
    Lawrentschuk N, Finelli A, Van der Kwast TH et al (2011) Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer. J Urol 185:862–868PubMedCrossRefGoogle Scholar
  16. 16.
    Stolzenburg JU, Bynens B, Do M, Rabenalt R, Katsakiori PF, Liatsikos E (2007) Salvage laparoscopic extraperitoneal radical prostatectomy after failed high-intensity focused ultrasound and radiotherapy for localized prostate cancer. Urology 70:956–960PubMedCrossRefGoogle Scholar
  17. 17.
    Chade DC, Eastham J, Graefen M et al (2012) Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 61:961–971PubMedCrossRefGoogle Scholar
  18. 18.
    Ficarra V, Novara G, Rosen RC et al (2012) Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 62:405–417PubMedCrossRefGoogle Scholar
  19. 19.
    Borboroglu PG, Sands JP, Roberts JL, Amling CL (2000) Risk factors for vesicourethral anastomotic stricture after radical prostatectomy. Urology 56:96–100PubMedCrossRefGoogle Scholar
  20. 20.
    Kostakopoulos A, Argiropoulos V, Protogerou V, Tekerlekis P, Melekos M (2004) Vesicourethral anastomotic strictures after radical retropubic prostatectomy: the experience of a single institution. Urol Int 72:17–20PubMedCrossRefGoogle Scholar
  21. 21.
    van den Ouden D, Hop WC, Schroder FH (1998) Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160:1392–1397PubMedCrossRefGoogle Scholar
  22. 22.
    Van Poppel H, Vekemans K, Da Pozzo L et al (2006) Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 42:1062–1067PubMedCrossRefGoogle Scholar
  23. 23.
    Loeb S, Smith ND, Roehl KA, Catalona WJ (2007) Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 69:1170–1175PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Souhil Lebdai
    • 1
    Email author
  • Arnaud Villers
    • 2
  • Eric Barret
    • 3
  • Cosmina Nedelcu
    • 1
  • Pierre Bigot
    • 1
  • Abdel-Rahmène Azzouzi
    • 1
  1. 1.Urology DepartmentCHU AngersAngers Cedex 9France
  2. 2.University Hospital of LilleLilleFrance
  3. 3.Institut Mutualiste Montsouris (IMM)ParisFrance

Personalised recommendations